HSB-510 / Tharimmune - LARVOL DELTA

Quatramer™ encapsulation of dual-targeted PI3-Kδ/HDAC6 inhibitor, HSB-510, suppresses growth of breast cancer. (PubMed, Bioeng Transl Med) - "The present study investigates the encapsulation of a PI3-Kδ/HDAC6 dual inhibitor into hybrid block copolymers (polylactic acid-methoxy polyethylene glycol; polylactic acid-polyethylene glycol-polypropylene glycol-polyethylene glycol-polylactic acid) (HSB-510) as a delivery system to target PI3-Kδ and HDAC6 pathways in breast cancer cells. The treatment with HSB-510 was without any significant effect on the body weights of the mice. These results demonstrate that a novel Quatramer encapsulation of a PI3-Kδ/HDAC6 dual inhibitor (HSB-510) represents an approach for the successful targeting of breast cancer and potentially other cancer types."

Journal • Breast Cancer • Oncology • Solid Tumor • MYC

Hillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & Leukemias (GlobeNewswire) - "Hillstream BioPharma, Inc....announced that an abstract highlighting the progress of the Quatramer-based dual-targeted PI3-Kδ/HDAC6 inhibitor, HSB-510, and navitoclax (BCL-XL/BCL-2 inhibitor) has been scheduled for presentation in a Poster Session at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida and will be published in the online Proceedings of the AACR....Preclinical studies have demonstrated that treating TNBC cells with HSB-510 is associated with substantial down regulation of the growth of TNBC cells both in vitro as well as in TNBC syngeneic mouse model. Furthermore, the results also indicated that treatment of TNBC cells with HSB-510 significantly inhibited MYC levels. These findings indicated that dual inhibitor HSB-510 is an effective agent targeting MYC and can be developed as effective therapy for multiple MYC-dependent tumor indications."

Preclinical • Breast Cancer • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • Triple Negative Breast Cancer

Novel quatramer nano-formulation of dual-targeted PI3-Kδ/HDAC6 inhibitor, HSB-510, suppresses growth of triple negative breast cancer (AACR 2022) - "The treatment with HSB-510 was without any significant effect on the body weights of the mice. These results demonstrate that a novel Quatramer nano-formulation of a novel PI3-Kδ/HDAC6 dual inhibitor (HSB-510) represents an approach for successful targeting of TNBC and potentially other cancer types."

Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • MYC

Hillstream BioPharma Announces Acceptance of Abstract at AACR 2022 Annual Meeting Highlighting HSB-510, a Novel Quatramer-based, First-in-Class Dual Inhibitor of HDAC6 and PI3K-delta Downregulating c-myc Expression (Yahoo Finance) - "Hillstream BioPharma...announced that an abstract highlighting the progress of the Quatramer-based dual-targeted HDAC6/PI3K-delta inhibitor, HSB-510, has been scheduled for presentation in a Poster Session at the 2022 American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisiana and will be published in the online Proceedings of the AACR. The complete title and text of the abstract will be posted to the AACR Online itinerary planner at 4:30 PM ET on Tuesday March 8, 2022."

Preclinical • Oncology